TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral inflammation and persistent immune activation within the central nervous system, ...

A trial found six weeks of yoga improved sleep quality and reduced fatigue in people with MS, suggesting its use as a ...

The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

A small study found MS patients reported improved quality of life and reduced depression after Ocrelizumab biosimilar treatment ...

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...